drugset
drugset / Trial / NCT06719128

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

NCT06719128 ↗

Phase 1 Completed 46 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.

Timeline

Start
2024-12-06
Primary completion
2025-08-25
Completion
2025-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Olomorasib Small molecule — Oral

Indications

liver disorder